Canada is on track to lose its measles elimination status as an outbreak that began a year ago continues to spread.
The United States could follow in the coming months.
The Canadian outbreak began in October 2024 in New Brunswick, a province on…
Expert judges determining the best of the best in healthcare innovation recognized OMRON Healthcare for its blood pressure monitors with AI-powered AFib detection
HOFFMAN ESTATES, Ill., Oct. 28, 2025 /PRNewswire/ — Judges in the prestigious Digital Health Hub Foundation 2025 Digital Health Awards recognized OMRON Healthcare as the Best in Class Winner in the Home Health Diagnostics & Monitoring category for its breakthrough blood pressure monitors with AI-powered AFib detection.
OMRON won Best in Class in the Digital Health Hub Foundation Digital Health Awards for its breakthrough blood pressure monitors with AI-powered AFib detection.
The Digital Health Awards heralded OMRON’s evolution of the blood pressure monitoring experience. OMRON blood pressure monitors featuring IntelliSense™ AFib detection, such as the 10 Series, automatically screen for atrial fibrillation during every blood pressure measurement.
The Digital Health Awards, which honor the best of the best in healthcare innovation, heralded OMRON’s evolution of the blood pressure monitoring experience. In a medical device first, OMRON blood pressure monitors featuring IntelliSense™ AFib detection automatically screen for atrial fibrillation during every blood pressure measurement and can provide early detection of elevated risk for a high stroke1, heart failure2, and dementia risk3.
“Our OMRON Healthcare team is thrilled to accept this Best in Class Digital Health Award,” said Alice Koehler, Managing Director of OMRON Healthcare North America. “The digital health category is rapidly maturing and there was a record-setting number of entrants in the competition this year. Thank you to the judges for recognizing our achievement in innovation that empowers people to take charge of their health.”
“OMRON applied more than 50 years of collaboration with doctors and service to consumers to develop this breakthrough technology,” said Koehler. “The latest AHA and ACC blood pressure guidelines urge regular blood pressure monitoring at home and earlier intervention on hypertension, especially for those over age 40 and for expectant moms throughout pregnancy.”
“Atrial fibrillation (AFib) is widely undiagnosed. The health risks of AFib increase for those with high blood pressure and women in menopause. With OMRON IntelliSense™ AFib detection, we are helping people act on this condition earlier than ever before,” added Koehler.
OMRON blood pressure monitors with IntelliSense™ AFib detection include the OMRON Platinum BP5465, OMRON 10 Series® BP7465, , OMRON Gold BP5360, and OMRON 7 Series® BP7360. These clinically validated blood pressure monitors are listed on the U.S. Blood Pressure Validated Device Listing (VDL), and sync with the OMRON connect app which tracks user readings, analyzes trends and habits, presents insights to explain data, and provides daily reminders and progress reports.
OMRON’s IntelliSense™ AFib detection incorporates over 300 mathematical indices into a machine-learning algorithm that analyzes the pressure pulse wave generated as the blood pressure monitor cuff inflates. A study published in the October 2024 Heart Rhythm Journal4 found that OMRON blood pressure monitors with the Intellisense™ AFib algorithm can detect disturbances specific to AFib with remarkable accuracy.
The FDA granted OMRON medical device authorization for Intellisense™ AFib via the agency’s De Novo classification5, a regulatory pathway for first-of-their-kind innovations.6
The Digital Health Hub Foundation Awards spotlight the most innovative healthtech companies transforming healthcare through technology and recognizing the companies making the biggest impact. Each year, the competition attracts groundbreaking companies from around the world, with the most impactful advancing to the final stage.
The 7th Annual Digital Health Awards announced the Best in Class and Rising Star winners across all categories during the Grand Finale at HLTH USA in Las Vegas on October 20, 2025. The awards were presented across multiple live stages and celebrated before an audience of global healthcare leaders, investors and innovators.
“This year’s winners represent the best of what digital health has to offer, innovation that is not only transformative, but practical, scalable, and ready to make an impact today. We are proud to celebrate these companies for their vision and commitment to improving healthcare,” said Mark H. Goldstein, Chairman of the Digital Health Hub Foundation.
About the Digital Health Hub Foundation
The Digital Health Hub Foundation’s mission is to support the world’s most innovative healthcare companies in scaling and growing. Since 2017, the organization’s 30,000-member community has been dedicated to fostering innovation, including early-to-late-stage healthcare companies, industry providers, payors, mentors, and investors. Through their annual awards, the Digital Health Hub Foundation brings together the healthcare industry to celebrate and validate the best of the best in health technology.
About OMRON Healthcare, Inc.
OMRON Healthcare, Inc., is the world’s leading manufacturer and distributor of personal heart health products and an innovator in technologies supporting respiratory and pain management care. With over 50 years of medical device category leadership, OMRON is passionate about empowering people to take charge of their health at home through precise technology. Its market-leading products include a full range of home blood pressure monitors, nebulizers and TENS devices. The company’s mission is Going for Zero, the elimination of heart attacks and strokes. With more than 400 million devices sold globally, OMRON provides the world’s most recommended blood pressure monitors by healthcare professionals. OMRON Healthcare strives to improve lives and contribute to a better society by developing innovations that help people prevent, treat, and manage their medical conditions. The company provides products and services in over 130 countries. For more information, visit OmronHealthcare.com.
1 CDC AFib and Stroke https://www.cdc.gov/heart-disease/about/atrial-fibrillation.html?CDC_AAref_Val=https://www.cdc.gov/heartdisease/atrial_fibrillation.htm
2 AFib and Heart Failure https://www.hopkinsmedicine.org/health/conditions-and-diseases/atrial-fibrillation/afib-complications
3 PubMed: AFib and dementia https://pmc.ncbi.nlm.nih.gov/articles/PMC10568548/
4 Heart Rhythm Journal, October 2024 https://www.heartrhythmjournal.com/article/S1547-5271(24)02520-7/fulltext
5 FDA De Novo https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/de-novo-classification-request
6 FDA De Novo AI First https://www.fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-device-uses-artificial-intelligence-help-detect-potential-signs-colon
SOURCE OMRON Healthcare
Louisiana officials waited 2 months after the state’s first pertussis (whooping cough)-related deaths in years—which occurred by late January—to encourage vaccination and more than 3 months to issue a statewide…
To mark the final week of Breast Cancer Awareness Month 2025, a group of 21 leading public health organisations is calling on the European Union to take decisive action against the ongoing threat of alcohol consumption as a cause…
Elon Musk has launched Grokipedia, a crowdsourced online encyclopedia that the billionaire seeks to position as a rival to Wikipedia.
Writing on social media, Musk said that Grokipedia.com is “now live” and its goal is the “truth, the whole truth and nothing but the truth.”
Musk has previously criticized Wikipedia for being filled with “propaganda” and called for people to stop donating to the site, which is run by a nonprofit. In September he announced that his artificial intelligence company xAI was working on Grokipedia.
READ MORE: Why does the AI-powered chatbot Grok post false, offensive things on X?
The Grokipedia site has a minimalist appearance with little beyond a search bar where users can type in queries. It states that it has 885,279 articles. Wikipedia, meanwhile, says it has more than 7 million articles in English.
Like Wikipedia, users can search for articles on various topics such as Taylor Swift, the baseball World Series, or Buckingham Palace.
While Wikipedia is written and edited by volunteers, it’s unclear how exactly Grokipedia articles are put together. Reports suggest the site is powered by the same xAI model that underpins Musk’s Grok chatbot, but some articles are seemingly adapted from Wikipedia.
As a huge trove of well-constructed sentences with little restriction on how it’s used, Wikipedia has been a key source used to train AI chatbots, including Grok’s rivals ChatGPT and Google’s Gemini. That’s one reason Republican lawmakers in the U.S. Congress said they launched an investigation in August of alleged “manipulation efforts” in Wikipedia’s editing process that could inject bias and undermine neutral points of view on its platform and the AI systems that rely on it.
READ MORE: Citing ‘disruptive’ edits, Wikipedia bars anonymous entries from Congress-linked computers
Wikipedia encourages its volunteer editors to cite nearly every sentence or paragraph with a primary source, and sentences not verified can be challenged and removed. Some of Grokipedia’s entries are thinly sourced, such as an entry on the Chola Dynasty of southern India that has three linked sources, compared to Wikipedia’s that has 113 linked sources plus dozens of referenced books.
Grokipedia’s entry on Wikipedia accuses the site of having “systemic ideological biases — particularly a left-leaning slant in coverage of political figures and topics.”
The San Francisco-based Wikimedia Foundation didn’t immediately respond to a request for comment Tuesday.
A free press is a cornerstone of a healthy democracy.
Support trusted journalism and civil dialogue.
PHOENIX — Use of tirzepatide (Mounjaro, Zepbound) was associated with significantly lower risks of death, hospitalization, and major…
Two directors from MultiVersus are striking out on their own, forming a new, independent game studio. The platform brawler’s production director, Justin Fischer, and technical director, Brock Feldman, have joined forces to launch a new endeavor…
Microwave and radiofrequency ablation are safe and effective alternatives to surgery in older participants with hyperparathyroidism, according to a study published October 28 in Radiology.
The finding is from a trial of the procedures in 153…
Kulicke and Soffa Industries, Inc. Announces CEO Transition
Lester Wong to Serve as Interim CEO; Board of Directors Initiates Process to Identify Permanent Successor; Dr. Fusen Chen to Retire for Health Reasons
SINGAPORE, Oct. 28, 2025 /PRNewswire/ — Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC) (“Kulicke & Soffa”, “K&S”, “we” or the “Company”) today announced that Dr. Fusen Chen has agreed to retire from his position as President and CEO, and as a member of the Board, effective December 1, 2025, due to health reasons. Following the effective date, Dr. Chen will serve as an advisor to the Board for a 12-month period. The Board has initiated a process to identify the Company’s next permanent CEO. The search will include internal and external candidates.
Effective immediately, the Board of Directors has appointed Lester Wong, the Company’s current Executive Vice President, Finance and IT and Chief Financial Officer, as the Company’s Interim CEO. As Dr. Chen transitions from his role and in leading up to his retirement, he will support Lester Wong in ensuring a smooth transition and handover. Mr. Wong will also continue in his existing roles during this transitional period.
“We are profoundly grateful to Fusen for his visionary leadership, unwavering commitment, and remarkable achievements during his nine-year tenure as CEO and President,” said Peter Kong, Chairman of the K&S Board. “Fusen’s dedication to innovation and operational excellence has enabled K&S to grow and create value for shareholders. His leadership has solidified the Company’s core served market positions while accelerating its position at the forefront of advanced packaging and dispense technologies. His legacy will continue to inspire our organization for years to come. On behalf of the Board and the entire K&S family, I extend our heartfelt thanks and wish Fusen good health and success in his next chapter.”
“It has been a great honor to serve as Kulicke & Soffa’s CEO,” said Dr. Fusen Chen, President and CEO of K&S. “I thank our incredible team for their support. Together, we have navigated unprecedented global challenges with resilience and agility while building on the 75-year track record of innovation to unlock new opportunities across our markets, drive significant growth and create value for our shareholders. I am proud to have been a part of this progress and have the utmost confidence in K&S’ future.”
Mr. Kong added, “The Board has commenced a comprehensive search to identify the right leader to continue driving K&S’ strong momentum, expand our market share, further enhance our diverse portfolio and help our customers address critical challenges in the industry. As Executive Vice President and CFO, Lester has played an instrumental role in the Company’s success and we are confident that he will continue to drive K&S’ growth and innovation during this interim period.”
Mr. Kong concluded, “Together with the Board, I will assist Lester and the Executive Leadership Team in ensuring the continuity of leadership, stability and strategic focus of the Company. We believe this collaborative approach is critical as the Company is ushering through a period of exciting growth, driven by continued core-market improvement and capacity expansion, coupled with strong demand in sectors like AI, electric vehicles, and power semiconductors. We are investing in next-generation solutions such as ATPremier MEM PlusTM and expanding our capabilities in fluxless thermocompression bonding and chiplet integration. With a solid financial foundation and a clear strategic roadmap, we are well-positioned to support our customers’ evolving needs and deliver long-term value.”
“I look forward to assuming the interim CEO position and working closely with Peter, the Board and the entire Executive Leadership Team as the Board conducts its search for a permanent CEO to lead K&S into its next phase,” said Lester Wong, Executive Vice President, Finance and IT and CFO of K&S. “I am confident in the clear strategy we’ve established, which positions us to continue driving our leadership across semiconductor assembly technology and unlock meaningful value for our shareholders.”
K&S Reaffirms its Fourth Quarter Fiscal 2025 Outlook
In connection with today’s announcement, the Company reaffirmed its fourth quarter fiscal 2025 outlook. The Company intends to announce its fourth quarter fiscal 2025 financial results on November 19, 2025.
About Lester Wong
Mr. Wong, 59, has been the Company’s Chief Financial Officer since December 2018, and was promoted to Executive Vice President, from Senior Vice President, on January 1, 2022. Prior to that, Mr. Wong served as General Counsel & Senior Vice President, Legal Affairs beginning in September 2011. Mr. Wong has over 20 years of legal leadership at U.S. listed and Asian-based companies, with a wealth of experience in global corporate law. Previously, Mr. Wong served as General Counsel and held other senior legal positions at publicly traded companies including Gigamedia Limited and CDC Corporation.
About Kulicke & Soffa
Kulicke & Soffa is a global leader in semiconductor assembly technology, advancing device performance across automotive, compute, industrial, memory and communications markets. Founded on innovation in 1951, K&S is uniquely positioned to overcome increasingly dynamic process challenges – creating and delivering long-term value by aligning technology with opportunity.
Contacts
Kulicke & Soffa
Marilyn Sim
Public Relations
+65-6880 9309
msim@kns.com
Kulicke & Soffa
Joseph Elgindy
Finance
+1-215-784-7500
investor@kns.com
SOURCE Kulicke & Soffa Industries, Inc.